El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

657427.pdf (2.3 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2016-05-05

Llicència de publicació

cc-by-nc-nd (c) Elsevier B.V., 2016
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/104762

CD26/DPPIV Inhibition alters the expression of immune response-related genes in the thymi of NOD mice

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.mce.2016.02.014

Resum

The transmembrane glycoprotein CD26 or dipeptidyl peptidase IV (DPPIV) is a multifunctional protein. In immune system, CD26 plays a role in T-cell function and is also involved in thymic maturation and emigration patterns. In preclinical studies, treatment with DPPIV inhibitors reduces insulitis and delays or even reverses the new onset of type 1 diabetes (T1D) in non-obese diabetic (NOD) mice. However, the specific mechanisms involved in these effects remain unknown. The aim of the present study was to investigate how DPPIV inhibition modifies the expression of genes in the thymus of NOD mice by microarray analysis. Changes in the gene expression of β-cell autoantigens and Aire in thymic epithelial cells (TECs) were also evaluated by using qRT-PCR. A DPPIV inhibitor, MK626, was orally administered in the diet for 4 and 6 weeks starting at 6-8 weeks of age. Thymic glands from treated and control mice were obtained for each study checkpoint. Thymus transcriptome analysis revealed that 58 genes were significantly over-expressed in MK626-treated mice after 6 weeks of treatment. Changes in gene expression in the thymus were confined mainly to the immune system, including innate immunity, chemotaxis, antigen presentation and immunoregulation. Most of the genes are implicated in central tolerance mechanisms through several pathways. No differences were observed in the expression of Aire and β-cell autoantigens in TECs. In the current study, we demonstrate that treatment with the DPPIV inhibitor MK626 in NOD mice alters the expression of the immune response-related genes in the thymus, especially those related to immunological central tolerance, and may contribute to the prevention of T1D.

Matèries

Diabetis, Microxips d'ADN, Expressió gènica, Ratolins (Animals de laboratori)

Matèries (anglès)

Diabetes, DNA microarrays, Gene expression, Mice (Laboratory animals)

Citació

Col·leccions

Articles publicats en revistes (Genètica, Microbiologia i Estadística)

Citació

JULIAN, María teresa, ALONSO, Nuria, COLOBRAN, Roger, SÀNCHEZ, Àlex (sànchez pla), MIÑARRO ALONSO, Antonio, PUJOL-AUTONELL, Irma, CARRASCAL, Jorge, RODRIGUEZ-FERNÁNDEZ, Silvia, AMPUDIA, Rosa maría, VIVES-PI, Marta, PUIG DOMINGO, Manuel. CD26/DPPIV Inhibition alters the expression of immune response-related genes in the thymi of NOD mice. _Molecular and Cellular Endocrinology_. 2016. Vol. 426, núm. 101-112. [consulta: 7 de gener de 2026]. ISSN: 0303-7207. [Disponible a: https://hdl.handle.net/2445/104762]

Exportar metadades

JSON - METS

Compartir registre